APGE
Apogee Therapeutics

374
Loading...
Loading...
News
all
press releases
Does Apogee Therapeutics Inc. (APGE) Have the Potential to Rally 72.52% as Wall Street Analysts Expect?
The consensus price target hints at a 72.5% upside potential for Apogee Therapeutics Inc. (APGE). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Zacks·7d ago
News Placeholder
More News
News Placeholder
Delta Air Lines, Tilray Brands, UiPath, Akero Therapeutics, Apogee Therapeutics: Stocks Making The Biggest Moves Today
Delta shares soared over 5% in Thursday’s afternoon trade after the airline’s third-quarter results beat Wall Street expectations.
Stocktwits·12d ago
News Placeholder
Wall Street Analysts See a 152.41% Upside in Apogee Therapeutics Inc. (APGE): Can the Stock Really Move This High?
The average of price targets set by Wall Street analysts indicates a potential upside of 152.4% in Apogee Therapeutics Inc. (APGE). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Zacks·3mo ago
News Placeholder
Wall Street Analysts See a 129.09% Upside in Apogee Therapeutics Inc. (APGE): Can the Stock Really Move This High?
Zacks·4mo ago
News Placeholder
Wall Street Analysts Think Apogee Therapeutics Inc. (APGE) Could Surge 132.72%: Read This Before Placing a Bet
Zacks·5mo ago
News Placeholder
XPeng & QuantumScape Are Among Top 11 Mid Cap Stocks That Performed Well Last Week (July 7-July 13): Details
10 mid-cap stocks jumped in last week, including QuantumScape, Lantheus Holdings, Sunrun, Kymera Therapeutics, Apogee Therapeutics, Joby Aviation, Crinetics Pharmaceuticals, Dyne Therapeutics, Summit...
Benzinga·1y ago
News Placeholder
Apogee (APGE) Stock Rallies 95.6% in a Month: Here's Why
Apogee Therapeutics Inc. APGE, a clinical-stage company, is focused on developing novel therapies for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease...
Zacks Investment Research·2y ago
News Placeholder
Apogee Therapeutics Announces First Participants Dosed in Phase 1 Trial of APG808, its Novel Half-life Extended IL-4R Antibody for the Treatment of Chronic Obstructive Pulmonary Disease (COPD) and Other Inflammatory Diseases
Preclinical data with APG808 demonstrate the potential for improved dosing over other treatment options in development, including the potential for dosing every six- or eight- weeks compared to...
Globe Newswire·2y ago
News Placeholder
Apogee Therapeutics (NASDAQ:APGE) Stock Price Up 6%
Apogee Therapeutics, Inc. (NASDAQ:APGE Get Free Report) rose 6% during trading on Friday . The company traded as high as $71.75 and last traded at $70.50. Approximately 222,641 shares traded...
Zolmax·2y ago
News Placeholder
Apogee Therapeutics, Inc. (NASDAQ:APGE) Given Average Rating of "Buy" by Analysts
Apogee Therapeutics, Inc. (NASDAQ:APGE Get Free Report) has been given a consensus recommendation of Buy by the seven ratings firms that are presently covering the firm...
Zolmax·2y ago

Latest APGE News

View

Advertisement|Remove ads.

Advertisement|Remove ads.